Chinese experts have successfully explored new to more local advanced thyroid cancer patients
Shanghai December 13 (Reporter Chen Jing) reporter 13th, I learned that Professor Wang Yu, director of the Head and Neck Surgery of the Affiliated Cancer Hospital of Fudan University, led the team’s innovative exploration to targeted the drug agonteini for new adjuvant treatment for local advanced thyroid cancer. The opportunity for advanced patients for surgery. This result is the first to successfully prove the effectiveness of Anttennib in the new auxiliary treatment of thyroid cancer. Professor Wang Yu published this thyroid cancer new aid in the international thyroid disease field authoritative journal "Thyroid) The results of the treatment of research were filled with a gap in the treatment of local advanced thyroid cancer.
Professor Wang Yu said on the 13th: "The multidisciplinary treatment based on surgical surgery is the main method of root the thyroid cancer." He said to the reporter: "But not all thyroid cancer patients It is lucky, some of the local advanced thyroid cancer patients in some loss of surgery, is not optimistic about the lack of treatment countermeasures.
"In order to enable more local advanced thyroid cancer to obtain surgery, Professor Wang Yu leads the team’s clinical study on targeting drugs with new auxiliary treatment of drugs.
In the case where the study was incorporated into a local advanced secondary thyroid cancer patient, nearly 70% of the patient had achieved the expected effect, and finally the radical resection surgery was successfully implemented. "This result is the first to successfully prove the effectiveness of Anttelli in the new adjuvant treatment of thyroid cancer. For advanced patients to go to surgery opportunities; more importantly, the new auxiliary treatment model is expected to become local advanced thyroid cancer treatment. The new choice. "Professor Wang Yu said.
It is reported that as one of China’s well-known thyroid cancer treatment center, the head neck surgery in the Affiliated Cancer Hospital of Fudan University has more than 110,000 years, and the 5-year survival rate of patients with thyroid cancer is diagnosed. It is comparable to the current international top thyroid cancer center.